Clinical Trial Update: Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial compares gemcitabine to a reduced-dose combination chemotherapy in fragile patients with non-resectable pancreatic cancer; the study is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-resectable Pancreatic Cancer
• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Morten Ladekarl | Conditions: Pancreas Cancer, Non-Resectable Pancreas Carcinoma | Phase 2 | Status: RECRUITING